New Paper- Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS

Abstract:

Evidence has accumulated since 2008 that intranasal, topical application of vasoactive intestinal polypeptide (VIP) can be administered safely to patients with a multi-system, multisymptom illness, called chronic inflammatory response syndrome (CIRS), acquired following exposure to biologically produced toxins and inflammagens. To date, over 300 physicians have prescribed intranasal VIP for their CIRS patients; these physicians have overwhelmingly (>90%) reported intranasal VIP to reduce symptoms; reduce elevated levels of MMP9, TGF beta-1 and C4a; raise low levels of VEGF; normalize clotting abnormalities, including acquired von Willebrand’s; and return regulation to pituitary systemic axes involving ACTH/cortisol and ADH/osmolality. These changes did not occur without use of VIP, though antecedent steps in a sequential treatment protocol provided benefit for many patients. The mechanism of these salutary health effects provided by VIP likely involves correction of abnormalities in ribosomal gene activation, nuclear encoded mitochondrial gene activation and an upregulation of Ikaros, a zinc fingered transcription factor. Recent preliminary work using sequential measurement of CNS volumes by NeuroQuant showed a longer treatment window (> 12 weeks) and higher doses of VIP (> 6 doses/day) safely corrected multinuclear atrophy of grey matter. The current study built upon this preliminary work and identified a course of VIP treatment that restores grey matter nuclear atrophy in CIRS patients. Safety of VIP and durability of benefit were both shown with no significant adverse effects reported by any patients.

Read the rest of this paper here!

Featured Resources

Urinary Mycotoxins: A Review of Contaminated Buildings and Food in Search of a Biomarker Separating Sick Patients from Controls

This review looks at the extensive published materials, including a definition of mycotoxins; a case definition for illness acquired following exposure to WDB from 2008 US GAO, multiple biomarkers, proteomics, transcriptomics, volumetric CNS imaging studies...

The fulfillment of hope from GENIE continues.

Beginning with the storage of frozen PAXgene tubes in 2008, “for use when the science caught up to what we learned from CIRS,” followed by whole transcriptome sequencing that showed rich veins of new information, to the current targeted findings of GENI...

The 2018 SM diagnostic module paper is now published! Read it here!

This comprehensive paper is the culmination of extensive collaboration between SM certified providers Scott McMahon MD, Karen Johnson MD, Ming Dooley, Lysander Jim MD, Yvonne Berry MD and Ritchie Shoemaker MD; James Ryan PhD and Michael Schrantz, IEP.

EMSL lab director acknowledges EPA investigation; offers free repeat ERMI

Beginning in late spring 2015, physicians from the Professionals Panel of Surviving Mold noted that something was odd with a variety of Environmental Relative Moldiness Index (ERMI) reports. A number of labs, including EMSL, appeared to not report low leve...

Dr. Joseph Brewer: Nasal Fungi, Anti-Fungals and Junk Science

In 2005, at the height of viciousness of mold litigation, defense interests loved using a California idea (“Geffcken”) that held that if a plaintiff couldn’t show the presence of the same mycotoxins in his body that were found in a wet building, then ...